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analysis.
Results: Based on a few studies, CM shows antioxidant, anti-
cytotoxic, anticlastogenesis and DNA damage inhibitory activities.
Abdulqader A.et al(2013) tested that camel milk inhibited inflam-
matory angiogenesis via downregulation of proangiogenic and
proinﬂammatory cytokines in mice. Hala M.F et al (2014)
reported that camel milk inhibited murine hepatic carcinogenesis,
initiated by diethyl nitrosamine and promoted by phenobarbitone
in male rats. CM also inhibits the progression of hepatocellular
carcinoma. M. Quita Salwa et al (2010) demonstrated antigeno-
toxic and anticytotoxic effects of camel milk in mice treated
with cisplatin.
Hesham M. Korashy, et al (2012) reported that camel milk trig-
gered apoptotic signaling pathways of human hepatoma HepG2
and breast cancer MCF7 cell lines through transcriptional
mechanisms.
Discussion: The main components of camel milk giving insight
into the its potential therapeutic benefits underlying the anticancer
actions are as follows:
1- The vitamin C content in camel’s milk is about three times
higher than that in cows’ milk. Ascorbic acid protects DNA against
oxidative damages.
2. The Selenium content of CM is comparable to those of other
types of milk. Selenium is a constituent of various oxidation defen-
sive selenioproteins and a cofactor of glutathione peroxidase in the
elimination of peroxide radicals.
3. The zinc content of camel’s milk was higher than that of human
milk. Zinc is an element required for DNA and RNA synthesis and
may be a cofactor in the activity of superoxide dismutase. The protec-
tive effect of zinc on cadmium Genotoxicity (the number of micro-
nucleated cells decreased) was observed.
4. The antimutagenic potential of casein was investigated using
several mutagens.
5- Camel milk lactoferrin reduces the proliferation of colorectal
cancer cells and exerts antioxidant and DNA damage inhibitory
activities.
6. There are high levels of linoleic acids (CLA) among the poly-
unsaturated fatty acids in camel milk. CLA compounds could serve as
useful food antioxidants and provide additional value because of their
potential bioactivity in disease prevention. The results obtained by
Liew et al. (1995) supported a mechanism involving the inhibition
of carcinogen activation by CLA, as opposed to direct interaction
with procarcinogen, scavenging of electrophiles or selective induction
of phase I detoxification pathways.
Conclusion: The results are indicative of the remarkable prop-
erties of camel milk in the control and treatment of cancer. The
main factor responsible for anticancer properties of camel milk is
not yet known. It is expected that the antioxidant properties of
camel milk plays an important role in its anticancer activities. In
order to prove the properties listed, clinical studies will be very
helpful.
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Extended Abstract
Introduction: Since microRNAs (miRNAs) discovery, the knowl-
edge on miRNAs and cancer has been increasing exponentially (Fig-
ure 1). The first miRNA was discovered in 1993 by Victor Ambros
and colleagues. By the year 2000, the Ambros and Ruvkun laborato-
ries had discovered the two founding members of a family of small
non-coding RNAs, now called miRNAs.
The detection of mature miRNA transcripts (21~22 nt transcripts)
originated from larger precursor transcript. Two processes are neces-
sary for generation of mature miRNAs: (i) pre-miRNAs from pri-
miRNAs in the nucleus by Drosha and (ii) processing of pre-miRNAs
into mature miRNAs in the cytoplasm by Dicer. The biological role
and in vivo functions of most mammalian miRNAs are very different.
In invertebrates, miRNAs regulate developmental timing, neuronal
differentiation, cell proliferation, growth control, and programmed
cell death. In mammals, miRNAs have been found to play a role in
embryogenesis and stem cell maintenance, hematopoietic cell differ-
entiation, and brain development. Till now, microRNAs expression
has been found to be deregulated in a wide range of human diseases
including cancer.
MiRNAs in cancer: The first report for miRNAs role in cancer,
only two years after the discovery of the first human miRNA, by
George Calin and colleagues was published. Up to day a lot of
papers show miRNAs play a role in tumor invasion and metastasis.
Many aspects of miRNAs roles such as MicroRNA networks in can-
cer, MicroRNAs as predictors of prognosis, MicroRNAs for classi-
fication of disease , MicroRNA polymorphisms predisposing
cancer, MicroRNAs as non-invasive biomarkers and MicroRNAs
as predictors of drug efficacy, was studied. One of the most impor-
tant challenges to overcome cancer is early identification by bio-
markers. A lot of studies highlight the potential of miRNAs as
biomarkers for cancer, Furthermore the mutational status of miRNA
binding sites in their protein coding targets can also be regarded as a
diagnostic tool. Also, exist to strategy for MiRNAs as therapeutic
agents. MiRNA inhibition was the first approach used to explore
the potential of miRNAs in cancer therapy. The second strategy of
miRNA therapeutics is to use miRNAs as a therapeutic agent as
a replacement strategy.
Conclusions: Over recent years, miRNAs have emerged as
major players in the complex networks of gene regulation and
have been implicated in various aspects of human disease. These
small RNAs have already significantly improved our understanding
of carcinogenesis. microRNAs represent critical regulators
of tumor cell differentiation, proliferation, cell cycle progression,
invasion and metastasis. Based on microRNA arrays various
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and many of them are used for diagnosis and as prognostic or pre-
dictive tools. But till now, two challenges are remained that
requires further study: (i) the safety profile of miRNAs and (ii)
clinic delivery.
Fig. 1. PubMed query for miRNAs and cancer (September 2015).Fig. 1. Various domains that are embedded in the protein sequence of the
Diphtheria toxin. As a instance of protein sequences characterization.
Fig. 2. Binding affinity of the SDC1 to corresponding specific antigens of
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Extended Abstract
Introduction: The term ‘‘brain tumours’’ refers to a mixed group
of neoplasms originating from intracranial tissues and the meninges
with degrees of malignancy ranging from benign to aggressive.
Each type of this malignancy has its own biology, and could be lethal
due to their site in the brain, their ability to infiltrate locally, and their
propensity to transform to malignancy. Consequently, the lack of
comprehensive science of brain tumours creates problems in describ-
ing the epidemiology and therapeutic approaches. So, despite advan-
ces in conventional treatment modalities for malignant brain tumors
the prognosis for patients with high-grade astrocytic tumor remains
dismal. However, conventional treatments are accompanied with
many problems in some instances such as bleeding, hair loss, diar-
rhea, development of multidrug resistance, and immunosuppression.
Irrespective the lack of science about brain tumours and problems
that are accompanied with conventional treatments, BBB is a major
obstacle in this cancer. Therefore, there is an urgent need for the
development of novel therapies. Ideally anticancer agents for this
tumor, while could be act exclusively against tumor cells, should
be have the ability to crossing the BBB without any side effects on
the human body. Advances in genomic and proteomic research indi-
cate that treatment of brain tumor patients can be increasingly person-
alized according to the characteristics of the targeted tumor and its
environment. Nonetheless, during the last two decades, a novel class
of investigative drug candidates, Tumor-targeting protein, for the
treatment of central nervous system neoplasia has emerged. Tumor-
targeting protein which generally called immunotoxins, are composed
of a toxic enzyme coupled to a specific cell binding domain that tar-
gets cancer-associated antigens. In this context, a growing number ofthem are in different phases of the clinical and preclinical pipeline.
Bearing in mind, we investigated to designing and evaluation a new
generation of immunotoxins with capacity to targeting tumor specific
antigens of glioma as well as crossing the BBB.
Materials and methods: In this study at the first step a profile of
specific antigen of tumor brains, bacteria and their therapeutic prod-
ucts, related receptors and corresponding affecting mechanisms were
gathered. With the aim of achieving the required nucleotide and pro-
tein sequences NCBI, Uniprot and ExPASy were used. Protein
sequence analyses were done with using web application software
including InterProScan 5, CD Search and Motif Scan. 3D structure
of selected products, as well as specific antigens and their matching
ligands were retrieved or prepared via PDB, SWISS-MODEL and
or Modeller programs. Furthermore, corresponding ligands of
selected antigens were determined by using of the String. Moreover,
the protein sequences of the selected products were analyzed via Pro-
tein Blast under various matrixes. Moreover, immunogenicity assays
were performed via SVMTriPt program. Finally, the efficiency of the
3D structure of designed immunotoxins were measured with Ram-
page and visualized via Pymol.
Result and conclusion: The results of therapeutic products profil-
ing led to discovery a comprehensive profile of protein toxins with
very diverse in the resource bacteria, effective dosage, structure and
functions. However, this investigation led to finding that some of
them have previously been used in immunotoxin structure. Therefore,
critical toxins were profiled and then characterized. The result of this
analysis represented Diphtheria toxin-induced deaths domains with
ribosyltransferase functionality (Figure 1).
On the other hand, similar analysis led to disclosure effective
death domains in various toxins including glucanase domain, exo-
toxin A middle domain, and so forth with various length and activity.
Furthermore, the results of homology protein searching led to the
detection a series of similar sequences of effective domains such as
Diphtheria toxin in other species of the bacteria such as Corynebac-
terium ulcerans that propounded as novel candidate for immunotox-
ins designing. However, some of domain searching didn't have any
